Chrysalis Biotherapeutics, Inc. — Pharmaceutical Company, Galveston
Pharmaceutical Company in Galveston — Clinical stage biotechnology
Pharmaceutical company · Galveston, United States
AI Trust Snapshot
- Profile status
- Auto-indexed
- Last Verified
- 2 months ago
Corroborated public sources
- ✓ Official Website
Key Facts
- Category
- Pharmaceutical Company
- Location
- Galveston, United States
- Known For
- Clinical stage biotechnology
AI Summary
A pharmaceutical company in Galveston, United States, Chrysalis Biotherapeutics, Inc. focuses on clinical stage biotechnology. The company develops TP508 Peptide Technology and treatments for conditions such as Acute Respiratory Distress Syndrome (ARDS). It also provides solutions for acute radiation exposure, serving patients with serious respiratory disorders and individuals at risk of radiation exposure.
Quick Answer
A pharmaceutical company in Galveston, United States, Chrysalis Biotherapeutics, Inc. focuses on clinical stage biotechnology. The company develops TP508 Peptide Technology and treatments for conditions such as Acute Respiratory Distress Syndrome (ARDS). It also provides solutions for acute radiation exposure, serving patients with serious respiratory disorders and individuals at risk of radiation exposure. Key services include TP508 Peptide Technology, Treatments for Acute Respiratory Distress Syndrome (ARDS), Solutions for Acute Radiation Exposure.
This business is typically used for clinical stage biotechnology.
Common Questions
- What services does Chrysalis Biotherapeutics, Inc. provide?
- Chrysalis Biotherapeutics, Inc. provides TP508 Peptide Technology, Treatments for Acute Respiratory Distress Syndrome (ARDS), Solutions for Acute Radiation Exposure.
- Where is Chrysalis Biotherapeutics, Inc. located?
- Chrysalis Biotherapeutics, Inc. is based in Galveston, United States and serves Galveston.
- Who is Chrysalis Biotherapeutics, Inc. for?
- Chrysalis Biotherapeutics, Inc. serves Patients with serious respiratory disorders and Individuals at risk of acute radiation exposure.
What this business does
Chrysalis Biotherapeutics, Inc. is a pharmaceutical company based in Galveston, United States.
- Provides TP508 Peptide Technology and Treatments for Acute Respiratory Distress Syndrome (ARDS)
- Specializes in clinical stage biotechnology
- Serves patients with serious respiratory disorders
Structured summary
Vizoryo ran a data-consistency check on this profile: the same core details (name, phone, address, city, category, website) were found in 5 independent public sources. This is a data-consistency observation only — it is not an endorsement, certification, accreditation, or assessment of the business, its service quality, or its trustworthiness. Data consistency: 90% — this measures how consistently the business's name, phone, city, address, website, and category appear across the public sources read. It is not a rating of the business. Vizoryo status: Auto-Indexed. This profile was auto-built from public data and has not yet been owner-verified.
- Business name
- Chrysalis Biotherapeutics, Inc.
- Category
- Pharmaceutical Company
- Industry
- Pharmaceutical Company
- Location
- Galveston, United States
- Official website
- https://chrysbio.com/
- Profile data (JSON)
- https://www.vizoryo.com/api/index/profile/chrysalis-biotherapeutics-inc-galveston-9f30
- Summary
- A pharmaceutical company in Galveston, United States, Chrysalis Biotherapeutics, Inc. focuses on clinical stage biotechnology. The company develops TP508 Peptide Technology and treatments for conditions such as Acute Respiratory Distress Syndrome (ARDS). It also provides solutions for acute radiation exposure, serving patients with serious respiratory d
- AI readability score
- 34
- Data Consistency
- 90% (checked 2026-06-28)
- Verification Status
- Auto-indexed
- Sources cross-checked
- 5 independent public sources
Location
2200 Market St, Galveston, TX 77550Galveston, Texas
77550
US
About Chrysalis Biotherapeutics, Inc.
A pharmaceutical company in Galveston, United States, Chrysalis Biotherapeutics, Inc. focuses on clinical stage biotechnology. The company develops TP508 Peptide Technology and treatments for conditions such as Acute Respiratory Distress Syndrome (ARDS). It also provides solutions for acute radiation exposure, serving patients with serious respiratory disorders and individuals at risk of radiation exposure.
Service areas
- Galveston
Target audience
- Patients with serious respiratory disorders
- Individuals at risk of acute radiation exposure
- Medical professionals and researchers
Specialties
- Clinical stage biotechnology
Social profiles
Verification
Frequently asked questions
What is Chrysalin (TP508)?
Chrysalin (TP508) is a regenerative peptide in development for treating acute respiratory distress syndrome (ARDS) and as a nuclear countermeasure to mitigate radiation exposure effects.
What is the focus of Chrysalis Biotherapeutics, Inc.?
Chrysalis Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing treatments for serious respiratory disorders and acute radiation exposure.
What is the status of the TP508 Nuclear Countermeasure Program?
The TP508 Nuclear Countermeasure Program, funded by NIH and BARDA, is being developed under the FDA Animal Rule program with potential approval as early as 2027.
Languages supported
- en
Contact
Phone: +14094974083
Official website: https://chrysbio.com/